Overview

The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma

Status:
Unknown status

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

- To assess the radiological response, curative resection rate of preoperative docetaxel/cisplatin/capecitabine(DCX). - To correlate treatment response with serum RUNX3 promoter hypermethylation. - To determine the toxicities of preoperative DCX - To determine the time to progression/overall survival of preoperative DCX

Phase:

Phase 2

Details

Lead Sponsor:

National University Hospital, Singapore

Treatments:

Capecitabine
Cisplatin
Docetaxel